Identifying and responding to fatigue and apathy in Parkinson’s disease: a review of current practice

References

• Titova N, Qamar MA, Chaudhuri KR. The Nonmotor Features of Parkinson’s Disease. Int Rev Neurobiol. 2017;132:33–54.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011 Feb 15;26(3):399–406.
   PubMed Web of Science ®Google Scholar
• Bruno AE, Sethares KA. Fatigue in Parkinson disease: an integrative review. J Neurosci Nurs. 2015 Jun;47(3):146–153.
   PubMedGoogle Scholar
• Kluger BM, Herlofson K, Chou KL, et al. Parkinson’s disease-related fatigue: A case definition and recommendations for clinical research. Mov Disord. 2016 May;31(5):625–631.
   PubMed Web of Science ®Google Scholar
• Nassif DV, Pereira JS. Fatigue in Parkinson’s disease: concepts and clinical approach. Psychogeriatrics. 2018 Mar;18(2):143–150.
   PubMed Web of Science ®Google Scholar
• Martino D, Tamburini T, Zis P, et al. An objective measure combining physical and cognitive fatigability: correlation with subjective fatigue in Parkinson’s disease. Parkinsonism Relat Disord. 2016;32:80–86.
   PubMed Web of Science ®Google Scholar
• Lou JS. Physical and mental fatigue in Parkinson’s disease: epidemiology, pathophysiology and treatment. Drugs Aging. 2009;26(3):195–208.
   PubMed Web of Science ®Google Scholar
• Pavese N, Metta V, Bose SK, et al. Fatigue in Parkinson’s disease is linked to striatal and limbic serotonergic dysfunction. Brain. 2010 Nov;133(11):3434–3443.
   PubMedGoogle Scholar
• Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the apathy evaluation scale. Psychiatry Res. 1991 Aug;38(2):143–162.
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Mayberg HS, Preziosi TJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1992;4(2):134–139. Spring.
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Merello M, Jorge R, et al. The syndromal validity and nosological position of apathy in Parkinson’s disease. Mov Disord. 2009 Jun 15;24(8):1211–1216.
   PubMed Web of Science ®Google Scholar
• den Brok MG, van Dalen JW, van Gool WA, et al. Apathy in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2015 May;30(6):759–769.
   PubMed Web of Science ®Google Scholar
• Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3(3): 243–254. Summer.
   PubMed Web of Science ®Google Scholar
• Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex. 2006 Jul;16(7):916–928.
   PubMed Web of Science ®Google Scholar
• Robert P, Onyike CU, Leentjens AF, et al. Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry. 2009 Mar;24(2):98–104. .
   PubMed Web of Science ®Google Scholar
• Friedman JH, Beck JC, Chou KL, et al. Fatigue in Parkinson’s disease: report from a multidisciplinary symposium. NPJ Parkinsons Dis. 2016;2. DOI:10.1038/npjparkd.2015.25.
   PubMed Web of Science ®Google Scholar
• Havlikova E, Rosenberger J, Nagyova I, et al. Impact of fatigue on quality of life in patients with Parkinson’s disease. Eur J Neurol. 2008 May;15(5):475–480. .
   PubMed Web of Science ®Google Scholar
• Kluger BM. Fatigue in Parkinson’s Disease. Int Rev Neurobiol. 2017;133:743–768.
   PubMed Web of Science ®Google Scholar
• Siciliano M, Trojano L, Santangelo G, et al. Fatigue in Parkinson’s disease: A systematic review and meta-analysis. Mov Disord. 2018 Nov;33(11):1712–1723.
   PubMed Web of Science ®Google Scholar
• Alves G, Wentzel-Larsen T, Larsen JP. Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurol. 2004 Nov 23;63(10):1908–1911.
   PubMed Web of Science ®Google Scholar
• Pedersen KF, Alves G, Bronnick K, et al. Apathy in drug-naive patients with incident Parkinson’s disease: the Norwegian ParkWest study. J Neurol. 2010 Feb;257(2):217–223.
   PubMed Web of Science ®Google Scholar
• Liu H, Ou R, Wei Q, et al. Apathy in drug-naive patients with Parkinson’s disease. Parkinsonism Relat Disord. 2017;44:28–32.
   PubMed Web of Science ®Google Scholar
• Dujardin K, Langlois C, Plomhause L, et al. Apathy in untreated early-stage Parkinson disease: relationship with other non-motor symptoms. Mov Disord. 2014 Dec;29(14):1796–1801.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Bronnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):928–930.
   PubMed Web of Science ®Google Scholar
• Ou R, Yang J, Cao B, et al. Progression of non-motor symptoms in Parkinson’s disease among different age populations: A two-year follow-up study. J Neurol Sci. 2016 Jan;15(360):72–77.
   Google Scholar
• Pagonabarraga J, Kulisevsky J, Strafella AP, et al. Apathy in Parkinson’s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol. 2015 May;14(5):518–531.
   PubMed Web of Science ®Google Scholar
• Pedersen KF, Larsen JP, Alves G, et al. Prevalence and clinical correlates of apathy in Parkinson’s disease: a community-based study. Parkinsonism Relat Disord. 2009 May;15(4):295–299.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord. 2009 Nov 15;24(15):2175–2186.
   PubMed Web of Science ®Google Scholar
• Kluger BM, Krupp LB, Enoka RM. Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy. Neurol. 2013 Jan 22;80(4):409–416.
   PubMed Web of Science ®Google Scholar
• Kostic VS, Tomic A, Jecmenica-Lukic M. The pathophysiology of fatigue in Parkinson’s disease and its pragmatic management. Mov Disord Clin Pract. 2016 Jul-Aug;3(4):323–330.
   PubMed Web of Science ®Google Scholar
• Schifitto G, Friedman JH, Oakes D, et al. Fatigue in levodopa-naive subjects with Parkinson disease. Neurol. 2008 Aug 12;71(7):481–485.
   PubMed Web of Science ®Google Scholar
• Chou KL, Kotagal V, Bohnen NI. Neuroimaging and clinical predictors of fatigue in Parkinson disease. Parkinsonism Relat Disord. 2016 Feb;23:45–49.
   PubMed Web of Science ®Google Scholar
• Chaudhuri A, Behan PO. Fatigue in neurological disorders. Lancet. 2004 Mar 20;363(9413):978–988.
   PubMed Web of Science ®Google Scholar
• Abe K, Takanashi M, Yanagihara T. Fatigue in patients with Parkinson’s disease. Behav Neurol. 2000;12(3):103–106.
   PubMed Web of Science ®Google Scholar
• Tessitore A, Giordano A, De Micco R, et al. Functional connectivity underpinnings of fatigue in “Drug-Naive” patients with Parkinson’s disease. Mov Disord. 2016 Oct;31(10):1497–1505.
   PubMed Web of Science ®Google Scholar
• Morris G, Berk M, Walder K, et al. Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. BMC Med. 2015 Feb 6;13:28.
   PubMed Web of Science ®Google Scholar
• Pereira JR, Santos LVD, Santos RMS, et al. IL-6 serum levels are elevated in Parkinson’s disease patients with fatigue compared to patients without fatigue. J Neurol Sci. 2016 Nov 15;370:153–156.
   PubMed Web of Science ®Google Scholar
• Lindqvist D, Hall S, Surova Y, et al. Cerebrospinal fluid inflammatory markers in Parkinson’s disease–associations with depression, fatigue, and cognitive impairment. Brain Behav Immun. 2013;33:183–189.
   PubMed Web of Science ®Google Scholar
• Kudo T, Loh DH, Truong D, et al. Circadian dysfunction in a mouse model of Parkinson’s disease. Exp Neurol. 2011 Nov;232(1):66–75.
   PubMed Web of Science ®Google Scholar
• Harrington ME. Neurobiological studies of fatigue. Prog Neurobiol. 2012 Nov;99(2):93–105.
   PubMed Web of Science ®Google Scholar
• Kataoka Y, Yamato M, Miyashige Y, et al. Neuroinflammation in animal models of fatigue [Research Article]. Adv Neuroimmune Biol. 2013;4(4):229–236.
   Google Scholar
• Magnard R, Vachez Y, Carcenac C, et al. What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson’s disease? Transl Psychiatry. 2016 Mar 8;6:e753.
   PubMed Web of Science ®Google Scholar
• Leroi I, Andrews M, McDonald K, et al. Apathy and impulse control disorders in Parkinson’s disease: a direct comparison. Parkinsonism Relat Disord. 2012 Feb;18(2):198–203.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009 May;8(5):464–474.
   PubMed Web of Science ®Google Scholar
• Czernecki V, Pillon B, Houeto JL, et al. Motivation, reward, and Parkinson’s disease: influence of dopatherapy. Neuropsychologia. 2002;40(13):2257–2267.
   PubMed Web of Science ®Google Scholar
• Czernecki V, Schupbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord. 2008 May 15;23(7):964–969.
   PubMed Web of Science ®Google Scholar
• Thobois S, Ardouin C, Lhommee E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: predictors and underlying mesolimbic denervation. Brain. 2010 Apr;133(Pt 4):1111–1127.
   PubMed Web of Science ®Google Scholar
• Remy P, Doder M, Lees A, et al. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005 Jun;128(Pt 6):1314–1322.
   PubMedGoogle Scholar
• Mayeux R, Stern Y, Williams JB, et al. Clinical and biochemical features of depression in Parkinson’s disease. Am J Psychiatry. 1986 Jun;143(6):756–759.
   PubMed Web of Science ®Google Scholar
• Maillet A, Krack P, Lhommee E, et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain. 2016 Sep;139(Pt 9):2486–2502.
   PubMedGoogle Scholar
• Devos D, Moreau C, Maltete D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):668–674.
   PubMed Web of Science ®Google Scholar
• Guimaraes HC, Levy R, Teixeira AL, et al. Neurobiology of apathy in Alzheimer’s disease. Arq Neuropsiquiatr. 2008 Jun;66(2B):436–443.
   PubMed Web of Science ®Google Scholar
• Reijnders JS, Scholtissen B, Weber WE, et al. Neuroanatomical correlates of apathy in Parkinson’s disease: A magnetic resonance imaging study using voxel-based morphometry. Mov Disord. 2010 Oct 30;25(14):2318–2325.
   PubMed Web of Science ®Google Scholar
• Skidmore FM, Yang M, Baxter L, et al. Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease. Neuroimage. 2013 Nov 1;81:484–495.
   PubMed Web of Science ®Google Scholar
• Levy R, Czernecki V. Apathy and the basal ganglia. J Neurol. 2006 Dec;253(Suppl 7):VII54–61.
   PubMedGoogle Scholar
• Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord. 2010 Apr 30;25(6):704–709.
   PubMed Web of Science ®Google Scholar
• Todorova A, Jenner P, Ray Chaudhuri K. Non-motor Parkinson’s: integral to motor Parkinson’s, yet often neglected. Pract Neurol. 2014 Oct;14(5):310–322.
   PubMedGoogle Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, et al. Neuropsychiatric symptoms and caregiver’s burden in Parkinson’s disease. Parkinsonism Relat Disord. 2015 Jun;21(6):629–634.
   PubMed Web of Science ®Google Scholar
• Herlofson K, Kluger BM. Fatigue in Parkinson’s disease. J Neurol Sci. 2017 Mar;15(374):38–41.
   Google Scholar
• Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurol. 2013 Feb 26;80(9):800–809.
   PubMed Web of Science ®Google Scholar
• Camargo CHF, Serpa RA, Jobbins VA, et al. Differentiating between apathy and depression in patients with Parkinson disease dementia. Am J Alzheimers Dis Other Demen. 2018 Feb;33(1):30–34.
   PubMed Web of Science ®Google Scholar
• Richard IH. Apathy does not equal depression in Parkinson disease: why we should care. Neurol. 2006 Jul 11;67(1):10–11.
   PubMed Web of Science ®Google Scholar
• Ishizaki J, Mimura M. Dysthymia and apathy: diagnosis and treatment. Depress Res Treat. 2011;2011:893905.
   PubMedGoogle Scholar
• Ishii S, Weintraub N, Mervis JR. Apathy: a common psychiatric syndrome in the elderly. J Am Med Dir Assoc. 2009 Jul;10(6):381–393.
   PubMed Web of Science ®Google Scholar
• Kirsch-Darrow L, Fernandez HH, Marsiske M, et al. Dissociating apathy and depression in Parkinson disease. Neurol. 2006 Jul 11;67(1):33–38.
   PubMed Web of Science ®Google Scholar
• Oguru M, Tachibana H, Toda K, et al. Apathy and depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2010 Mar;23(1):35–41.
   PubMed Web of Science ®Google Scholar
• Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009 Aug 15;24(11):1641–1649.
   PubMed Web of Science ®Google Scholar
• Benito-Leon J, Cubo E, Coronell C, et al. Impact of apathy on health-related quality of life in recently diagnosed Parkinson’s disease: the ANIMO study. Mov Disord. 2012 Feb;27(2):211–218.
   PubMed Web of Science ®Google Scholar
• Guimaraes HC, Fialho PP, Carvalho VA, et al. Apathy is not associated with performance in brief executive tests in patients with mild cognitive impairment and mild Alzheimer’s disease. Curr Alzheimer Res. 2014;11(8):792–798.
   PubMed Web of Science ®Google Scholar
• Khoo TK, Yarnall AJ, Duncan GW, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurol. 2013 Jan 15;80(3):276–281.
   PubMed Web of Science ®Google Scholar
• Leroi I, Pantula H, McDonald K, et al. Neuropsychiatric symptoms in Parkinson’s disease with mild cognitive impairment and dementia. Parkinsons Dis. 2012;2012:308097.
   PubMed Web of Science ®Google Scholar
• Martin GP, McDonald KR, Allsop D, et al. Apathy as a behavioural marker of cognitive impairment in Parkinson’s disease: a longitudinal analysis. J Neurol. 2020 Jan;267(1):214–227.
   PubMed Web of Science ®Google Scholar
• Bottini Bonfanti A, Etcheverry JL, Persi GG, et al. [Apathy in Parkinson’s disease. Impairment in quality of life]. Medicina (B Aires). 2009;69(2):253–258.
   PubMedGoogle Scholar
• Leroi I, Harbishettar V, Andrews M, et al. Carer burden in apathy and impulse control disorders in Parkinson’s disease. Int J Geriatr Psychiatry. 2012 Feb;27(2):160–166.
   PubMed Web of Science ®Google Scholar
• Schrag A, Hovris A, Morley D, et al. Caregiver-burden in parkinson’s disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord. 2006 Jan;12(1):35–41.
   PubMed Web of Science ®Google Scholar
• Cramer CK, Friedman JH, Amick MM. Olfaction and apathy in Parkinson’s disease. Parkinsonism Relat Disord. 2010 Feb;16(2):124–126.
   PubMed Web of Science ®Google Scholar
• Leroi I, Perera N, Harbishettar V, et al. Apathy and emotional blunting in Parkinson’s disease [Research Article]. 2014; Brain Disord Ther;3(5):2.
   Google Scholar
• Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord. 2007 Oct 15;22(13):1901–1911.
   PubMed Web of Science ®Google Scholar
• Metta V, Logishetty K, Martinez-Martin P, et al. The possible clinical predictors of fatigue in Parkinson’s disease: a study of 135 patients as part of international nonmotor scale validation project. Parkinsons Dis. 2011;2011:125271.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Schrag A, Weintraub D, et al. Pilot Study of the International Parkinson and Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS). Mov Disord Clin Pract. 2019 Mar;6(3):227–234.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schrag A, Weintraub D, et al. The movement disorder society nonmotor rating scale: initial validation study. Mov Disord. 2020 Jan;35(1):116–133.
   PubMed Web of Science ®Google Scholar
• Friedman JH, Alves G, Hagell P, et al. Fatigue rating scales critique and recommendations by the movement disorders society task force on rating scales for Parkinson’s disease. Mov Disord. 2010 May 15;25(7):805–822.
   PubMed Web of Science ®Google Scholar
• Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989 Oct;46(10):1121–1123.
   PubMed Web of Science ®Google Scholar
• Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. J Psychosom Res. 1993 Oct;37(7):753–762.
   PubMed Web of Science ®Google Scholar
• Smets EM, Garssen B, Bonke B, et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995 Apr;39(3):315–325.
   PubMed Web of Science ®Google Scholar
• Mendonca DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord. 2007 Oct 31;22(14):2070–2076.
   PubMed Web of Science ®Google Scholar
• Brown RG, Dittner A, Findley L, et al. The Parkinson fatigue scale. Parkinsonism Relat Disord. 2005 Jan;11(1):49–55.
   PubMed Web of Science ®Google Scholar
• Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011 May;10(5):415–423.
   PubMed Web of Science ®Google Scholar
• Morita A, Okuma Y, Kamei S, et al. Pramipexole reduces the prevalence of fatigue in patients with Parkinson’s disease. Intern Med. 2011;50(19):2163–2168.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Wetmore JB, Arbelo JM, et al. Validation study of the Parkinson’s fatigue scale in advanced Parkinson’s disease. Patient Relat Outcome Meas. 2019;10:141–152.
   PubMed Web of Science ®Google Scholar
• Hagell P, Hoglund A, Reimer J, et al. Measuring fatigue in Parkinson’s disease: a psychometric study of two brief generic fatigue questionnaires. J Pain Symptom Manag. 2006 Nov;32(5):420–432.
   PubMed Web of Science ®Google Scholar
• Fisk JD, Doble SE. Construction and validation of a fatigue impact scale for daily administration (D-FIS). Qual Life Res. 2002 May;11(3):263–272.
   PubMed Web of Science ®Google Scholar
• Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007 Jul;4(7):28–37.
   PubMedGoogle Scholar
• Chong R, Albor L, Wakade C, et al. The dimensionality of fatigue in Parkinson’s disease. J Transl Med. 2018 Jul 11;16(1):192.
   PubMedGoogle Scholar
• Leentjens AF, Dujardin K, Marsh L, et al. Apathy and anhedonia rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008 Oct 30;23(14):2004–2014.
   PubMed Web of Science ®Google Scholar
• Santangelo G, Barone P, Cuoco S, et al. Apathy in untreated, de novo patients with Parkinson’s disease: validation study of apathy evaluation scale. J Neurol. 2014 Dec;261(12):2319–2328.
   PubMed Web of Science ®Google Scholar
• Clarke DE, Reekum R, Simard M, et al. Apathy in dementia: an examination of the psychometric properties of the apathy evaluation scale. J Neuropsychiatry Clin Neurosci. 2007;19(1):57–64. Winter.
   PubMed Web of Science ®Google Scholar
• Lueken U, Evens R, Balzer-Geldsetzer M, et al. Psychometric properties of the apathy evaluation scale in patients with Parkinson’s disease. Int J Methods Psychiatr Res. 2017; Dec;26(4):e1564.
   Web of Science ®Google Scholar
• Costa A, Peppe A, Zabberoni S, et al. Apathy in individuals with Parkinson’s disease associated with mild cognitive impairment. A neuropsychological investigation. Neuropsychologia. 2018 Sep;118(Pt B):4–11.
   PubMedGoogle Scholar
• Wang Y, Li Y, Zhang X, et al. Apathy following bilateral deep brain stimulation of subthalamic nucleus in Parkinson’s disease: a meta-analysis. Parkinsons Dis. 2018;2018:9756468.
   PubMed Web of Science ®Google Scholar
• Pluck GC, Brown RG. Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):636–642.
   PubMed Web of Science ®Google Scholar
• Morita H, Kannari K. Reliability and validity assessment of an apathy scale for home-care patients with Parkinson’s disease: a structural equation modeling analysis. J Phys Ther Sci. 2016 Jun;28(6):1724–1727.
   PubMedGoogle Scholar
• Pedersen KF, Alves G, Larsen JP, et al. Psychometric properties of the starkstein apathy scale in patients with early untreated Parkinson disease. Am J Geriatr Psychiatry. 2012 Feb;20(2):142–148. .
   PubMed Web of Science ®Google Scholar
• Hauser RA, Slawek J, Barone P, et al. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease. BMC Neurol. 2016 Jun 7;16(1):90.
   PubMedGoogle Scholar
• Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013 May;136(5):1568–1577. .
   PubMed Web of Science ®Google Scholar
• Drapier D, Drapier S, Sauleau P, et al. Does subthalamic nucleus stimulation induce apathy in Parkinson’s disease? J Neurol. 2006 Aug;253(8):1083–1091. .
   PubMed Web of Science ®Google Scholar
• Sockeel P, Dujardin K, Devos D, et al. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2006 May;77(5):579–584. .
   PubMed Web of Science ®Google Scholar
• Garcia-Ramos R, Villanueva Iza C, Catalan MJ, et al. Validation of a Spanish version of the Lille apathy rating scale for Parkinson’s disease. Sci World J. 2014;2014:849834.
   Google Scholar
• Cummings JL. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurol. 1997 May;48(5 Suppl 6):S10–6.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007 Jan;78(1):36–42. .
   PubMed Web of Science ®Google Scholar
• Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression. J Neuropsychiatry Clin Neurosci. 1998 Summer;10(3):314–319. .
   PubMed Web of Science ®Google Scholar
• Oh YS, Lee JE, Lee PH, et al. Neuropsychiatric symptoms in Parkinson’s disease dementia are associated with increased caregiver burden. J Mov Disord. 2015 Jan;8(1):26–32. .
   PubMed Web of Science ®Google Scholar
• Aarsland D, Karlsen K. Neuropsychiatric aspects of Parkinson’s disease. Curr Psychiatry Rep. 1999 Oct;1(1):61–68.
   PubMedGoogle Scholar
• Ardouin C, Chereau I, Llorca PM, et al. [Assessment of hyper- and hypodopaminergic behaviors in Parkinson’s disease]. Rev Neurol (Paris). 2009 Nov;165(11):845–856. .
   PubMed Web of Science ®Google Scholar
• Robert PH, Clairet S, Benoit M, et al. The apathy inventory: assessment of apathy and awareness in Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment. Int J Geriatr Psychiatry. 2002 Dec;17(12):1099–1105. .
   PubMed Web of Science ®Google Scholar
• Grace J, Stout JC, Malloy PF. Assessing frontal lobe behavioral syndromes with the frontal lobe personality scale. Assess. 1999 Sep;6(3):269–284.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord. 2007 Jan;22(1):41–47. .
   PubMed Web of Science ®Google Scholar
• Friedman JH, Chou KL. Sleep and fatigue in Parkinson’s disease. Parkinsonism Relat Disord. 2004 May;10(Suppl 1):S27–35.
   PubMedGoogle Scholar
• Garber CE, Friedman JH. Effects of fatigue on physical activity and function in patients with Parkinson’s disease. Neurol. 2003 Apr 8;60(7):1119–1124.
   PubMed Web of Science ®Google Scholar
• Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019 Feb;34(2):180–198. .
   PubMed Web of Science ®Google Scholar
• Lou JS, Kearns G, Benice T, et al. Levodopa improves physical fatigue in Parkinson’s disease: a double-blind, placebo-controlled, crossover study. Mov Disord. 2003 Oct;18(10):1108–1114. .
   PubMed Web of Science ®Google Scholar
• Ray Chaudhuri K, Martinez-Martin P, Antonini A, et al. Rotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013 Jul;19(7):660–665. .
   PubMed Web of Science ®Google Scholar
• Wang HT, Wang L, He Y, et al. Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson’s disease: A meta-analysis of randomized placebo-controlled trials. J Neurol Sci. 2018 Oct 15;393:31–38. .
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011 Jan;26(1):90–99. .
   PubMed Web of Science ®Google Scholar
• Antonini A, Bauer L, Dohin E, et al. Effects of rotigotine transdermal patch in patients with Parkinson’s disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol. 2015 Oct;22(10):1400–1407. .
   PubMed Web of Science ®Google Scholar
• Chung SJ, Lee JJ, Ham JH, et al. Apathy and striatal dopamine defects in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord. 2016; Feb; 23:62–65.
   PubMed Web of Science ®Google Scholar
• Shannon KM, Bennett JP, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group. Neurol. 1997 Sep;49(3):724–728.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Schapira AH, Rascol O, et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson’s disease. Mov Disord. 2010 Nov 15;25(15):2542–2549.
   PubMed Web of Science ®Google Scholar
• Leentjens AF, Koester J, Fruh B, et al. The effect of pramipexole on mood and motivational symptoms in Parkinson’s disease: a meta-analysis of placebo-controlled studies. Clin Ther. 2009 Jan;31(1):89–98. .
   PubMed Web of Science ®Google Scholar
• Perez-Perez J, Pagonabarraga J, Martinez-Horta S, et al. Head-to-head comparison of the neuropsychiatric effect of dopamine agonists in Parkinson’s disease: a prospective, cross-sectional study in non-demented patients. Drugs Aging. 2015 May;32(5):401–407. .
   PubMed Web of Science ®Google Scholar
• Oguro H, Kadota K, Ishihara M, et al. Efficacy of pramipexole for treatment of apathy in Parkinson’s disease. Int J Clin Med. 2014;5(15):5.
   Google Scholar
• Lim TT, Kluger BM, Rodriguez RL, et al. Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease. Mov Disord. 2015 Nov;30(13):1825–1830. .
   PubMed Web of Science ®Google Scholar
• Rios Romenets S, Creti L, Fichten C, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – a randomized study. Parkinsonism Relat Disord. 2013 Jul;19(7):670–675. .
   PubMed Web of Science ®Google Scholar
• Wongpakaran N, van Reekum R, Wongpakaran T, et al. Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study. Ann Gen Psychiatry. 2007 Feb 21;6(1):7.
   PubMedGoogle Scholar
• Hoehn-Saric R, Lipsey JR, McLeod DR. Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol. 1990 Oct;10(5):343–345.
   PubMed Web of Science ®Google Scholar
• Zahodne LB, Bernal-Pacheco O, Bowers D, et al. Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson’s disease? J Neuropsychiatry Clin Neurosci. 2012;24(3):326–330. Summer. .
   PubMed Web of Science ®Google Scholar
• Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995 Sep;56(9):395–401.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson’s disease. Neurol. 1984 Aug;34(8):1092–1094.
   PubMedGoogle Scholar
• Corcoran C, Wong ML, O’Keane V. Bupropion in the management of apathy. J Psychopharmacol. 2004 Mar;18(1):133–135.
   PubMed Web of Science ®Google Scholar
• Pena E, Mata M, Lopez-Manzanares L, et al. Antidepressants in Parkinson’s disease. Recommendations by the movement disorder study group of the Neurological Association of Madrid. Neurologia. 2016 Mar 19. 33(6):395–402.
   Web of Science ®Google Scholar
• Maruyama T. New treatment of depression in Parkinson’s disease. Int J Psychiatry Clin Pract. 2003;7(Suppl 1):25–27.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Fayle R, Atassi F, et al. Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1636–1639. .
   PubMed Web of Science ®Google Scholar
• Elbers RG, Berendse HW, Kwakkel G. Treatment of fatigue in Parkinson disease. JAMA. 2016 Jun 7;315(21):2340–2341.
   PubMed Web of Science ®Google Scholar
• Lou JS, Dimitrova DM, Park BS, et al. Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study. Clin Neuropharmacol. 2009 Nov-Dec;32(6):305–310. .
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2002;14(4):461–462. Fall. .
   PubMed Web of Science ®Google Scholar
• Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson’s disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol. 2012 Jul;11(7):589–596. .
   PubMed Web of Science ®Google Scholar
• Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurol. 2012 Aug 14;79(7):651–658.
   PubMed Web of Science ®Google Scholar
• Oh YS, Kim JS, Lee PH. Effect of rivastigmine on behavioral and psychiatric symptoms of Parkinson’s disease dementia. J Mov Disord. 2015 May;8(2):98–102.
   PubMed Web of Science ®Google Scholar
• Vanle B, Olcott W, Jimenez J, et al. NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease. Transl Psychiatry. 2018 Jun 15;8(1):117.
   PubMedGoogle Scholar
• Ondo WG, Shinawi L, Davidson A, et al. Memantine for non-motor features of Parkinson’s disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism Relat Disord. 2011 Mar;17(3):156–159. .
   PubMed Web of Science ®Google Scholar
• Taus C, Giuliani G, Pucci E, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2003;(2):CD002818.
   Google Scholar
• Rodriguez-Moran M, Gonzalez-Gonzalez G, Bermudez-Barba MV, et al. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial. Clin Nephrol. 2006 Jul;66(7):3–10. .
   PubMedGoogle Scholar
• Martinez-Martin P, Reddy P, Antonini A, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis. 2011;1(2):197–203. .
   PubMedGoogle Scholar
• Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015 Apr;30(4):510–516. .
   PubMed Web of Science ®Google Scholar
• Dafsari HS, Martinez-Martin P, Rizos A, et al. EuroInf 2: subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson’s disease. Mov Disord. 2019 Mar;34(3):353–365. .
   PubMed Web of Science ®Google Scholar
• Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009 Jul 30;24(10):1468–1474.
   PubMed Web of Science ®Google Scholar
• Antonini A, Poewe W, Chaudhuri KR, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord. 2017; Dec; 45:13–20.
   PubMed Web of Science ®Google Scholar
• Chou KL, Persad CC, Patil PG. Change in fatigue after bilateral subthalamic nucleus deep brain stimulation for Parkinson’s disease. Parkinsonism Relat Disord. 2012 Jun;18(5):510–513.
   PubMed Web of Science ®Google Scholar
• Dafsari HS, Reddy P, Herchenbach C, et al. Beneficial effects of bilateral subthalamic stimulation on non-motor symptoms in Parkinson’s disease. Brain Stimul. 2016 Jan-Feb;9(1):78–85. .
   PubMed Web of Science ®Google Scholar
• Rouaud T, Lardeux S, Panayotis N, et al. Reducing the desire for cocaine with subthalamic nucleus deep brain stimulation. Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1196–1200.
   PubMed Web of Science ®Google Scholar
• Vachez Y, Carcenac C, Magnard R, et al. Subthalamic nucleus stimulation impairs motivation: implication for apathy in Parkinson’s disease. Mov Disord. 2020 Jan 13. DOI:10.1002/mds.27953.
   PubMedGoogle Scholar
• Le Jeune F, Drapier D, Bourguignon A, et al. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurol. 2009 Nov 24;73(21):1746–1751.
   PubMed Web of Science ®Google Scholar
• Lhommee E, Wojtecki L, Czernecki V, et al. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson’s disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol. 2018 Mar;17(3):223–231. .
   PubMed Web of Science ®Google Scholar
• Abbes M, Lhommee E, Thobois S, et al. Subthalamic stimulation and neuropsychiatric symptoms in Parkinson’s disease: results from a long-term follow-up cohort study. J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):836–843. .
   PubMed Web of Science ®Google Scholar
• Elder GJ, Taylor JP. Transcranial magnetic stimulation and transcranial direct current stimulation: treatments for cognitive and neuropsychiatric symptoms in the neurodegenerative dementias? Alzheimers Res Ther. 2014;6(9):74.
   PubMed Web of Science ®Google Scholar
• Qin B, Chen H, Gao W, et al. Effectiveness of high-frequency repetitive transcranial magnetic stimulation in patients with depression and Parkinson’s disease: a meta-analysis of randomized, controlled clinical trials. Neuropsychiatr Dis Treat. 2018;14:273–284.
   PubMed Web of Science ®Google Scholar
• Boggio PS, Fregni F, Bermpohl F, et al. Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson’s disease and concurrent depression. Mov Disord. 2005 Sep;20(9):1178–1184. .
   PubMed Web of Science ®Google Scholar
• Feil D, Razani J, Boone K, et al. Apathy and cognitive performance in older adults with depression. Int J Geriatr Psychiatry. 2003 Jun;18(6):479–485. .
   PubMed Web of Science ®Google Scholar
• Santangelo G, Vitale C, Trojano L, et al. Relationship between depression and cognitive dysfunctions in Parkinson’s disease without dementia. J Neurol. 2009 Apr;256(4):632–638. .
   PubMed Web of Science ®Google Scholar
• Maruo T, Hosomi K, Shimokawa T, et al. High-frequency repetitive transcranial magnetic stimulation over the primary foot motor area in Parkinson’s disease. Brain Stimul. 2013 Nov;6(6):884–891. .
   PubMed Web of Science ®Google Scholar
• Fernandez H, Bowers D The Michael J. Fox Foundation for Parkinson’s Research. 2006. https://www.michaeljfox.org/grant/restore-study https://www.michaeljfox.org/grant/restore-study2006.
   Google Scholar
• Oguro HNT, Mitaki S, Ishihara M, et al. Randomized Trial of Repetitive Transcranial Magnetic Stimulation for Apathy and Depression in Parkinson’s Disease.J Neurol Neurophysiol. 2014 [Oct 31];5(6):1–6. .
   Google Scholar
• Wilkinson D, Podlewska A, Banducci SE, et al. Caloric vestibular stimulation for the management of motor and non-motor symptoms in parkinson’s disease: intention-to-treat data. Data Brief. 2019; Aug; 25:104228.
   PubMed Web of Science ®Google Scholar
• Donoyama N, Ohkoshi N. Effects of traditional Japanese massage therapy on various symptoms in patients with Parkinson’s disease: a case-series study. J Altern Complement Med. 2012 Mar;18(3):294–299.
   PubMed Web of Science ®Google Scholar
• Kluger BM, Rakowski D, Christian M, et al. Randomized, controlled trial of acupuncture for fatigue in Parkinson’s disease. Mov Disord. 2016 Jul;31(7):1027–1032. .
   PubMed Web of Science ®Google Scholar
• Kong KH, Ng HL, Li W, et al. Acupuncture in the treatment of fatigue in Parkinson’s disease: A pilot, randomized, controlled, study. Brain Behav. 2018 Jan;8(1):e00897. .
   PubMed Web of Science ®Google Scholar
• Canning CG, Allen NE, Dean CM, et al. Home-based treadmill training for individuals with Parkinson’s disease: a randomized controlled pilot trial. Clin Rehabil. 2012 Sep;26(9):817–826. .
   PubMed Web of Science ®Google Scholar
• Winward C, Sackley C, Meek C, et al. Weekly exercise does not improve fatigue levels in Parkinson’s disease. Mov Disord. 2012 Jan;27(1):143–146. .
   PubMed Web of Science ®Google Scholar
• Butterfield LC, Cimino CR, Salazar R, et al. The Parkinson’s Active Living (PAL) Program. J Geriatr Psychiatry Neurol. 2017 Jan;30(1):11–25. .
   PubMed Web of Science ®Google Scholar
• Verkaik R, van Weert JC, Francke AL. The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review. Int J Geriatr Psychiatry. 2005 Apr;20(4):301–314.
   PubMed Web of Science ®Google Scholar
• Sauerbier A, Jenner P, Todorova A, et al. Non motor subtypes and Parkinson’s disease. Parkinsonism Relat Disord. 2016 Jan;22(Suppl 1):S41–6. .
   PubMed Web of Science ®Google Scholar
• Titova N, Chaudhuri KR. Non-motor Parkinson disease: new concepts and personalised management. Med J Aust. 2018 May 21;208(9):404–409.
   PubMed Web of Science ®Google Scholar
• Cummings J, Friedman JH, Garibaldi G, et al. Apathy in neurodegenerative diseases: recommendations on the design of clinical trials. J Geriatr Psychiatry Neurol. 2015 Sep;28(3):159–173.
   PubMed Web of Science ®Google Scholar
• Boersma I, Jones J, Carter J, et al. Parkinson disease patients’ perspectives on palliative care needs: what are they telling us? Neurol Clin Pract. 2016 Jun;6(3):209–219.
   PubMedGoogle Scholar
• Bouca-Machado R, Titova N, Chaudhuri KR, et al. Palliative Care for Patients and Families With Parkinson’s Disease. Int Rev Neurobiol. 2017;132:475–509.
   PubMed Web of Science ®Google Scholar